Christopher Liu
Stock Analyst at Leerink Partners
(3.00)
# 1,492
Out of 5,091 analysts
9
Total ratings
83.33%
Success rate
44.5%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Christopher Liu
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| EXEL Exelixis | Upgrades: Outperform | $48 | $42.17 | +13.82% | 2 | Oct 21, 2025 | |
| LYEL Lyell Immunopharma | Initiates: Buy | $20 | $28.36 | -29.48% | 1 | Sep 26, 2025 | |
| ADAG Adagene | Initiates: Buy | $9 | $1.99 | +352.26% | 1 | Sep 18, 2025 | |
| GNLX Genelux | Initiates: Buy | $10 | $4.37 | +128.83% | 1 | Jul 21, 2025 | |
| RLAY Relay Therapeutics | Maintains: Outperform | $19 → $18 | $7.63 | +135.91% | 1 | Dec 4, 2024 | |
| IDYA IDEAYA Biosciences | Downgrades: Market Perform | $41 → $27 | $35.34 | -23.60% | 2 | Nov 5, 2024 | |
| NUVL Nuvalent | Initiates: Market Perform | $42 | $107.87 | -61.06% | 1 | Aug 8, 2023 |
Exelixis
Oct 21, 2025
Upgrades: Outperform
Price Target: $48
Current: $42.17
Upside: +13.82%
Lyell Immunopharma
Sep 26, 2025
Initiates: Buy
Price Target: $20
Current: $28.36
Upside: -29.48%
Adagene
Sep 18, 2025
Initiates: Buy
Price Target: $9
Current: $1.99
Upside: +352.26%
Genelux
Jul 21, 2025
Initiates: Buy
Price Target: $10
Current: $4.37
Upside: +128.83%
Relay Therapeutics
Dec 4, 2024
Maintains: Outperform
Price Target: $19 → $18
Current: $7.63
Upside: +135.91%
IDEAYA Biosciences
Nov 5, 2024
Downgrades: Market Perform
Price Target: $41 → $27
Current: $35.34
Upside: -23.60%
Nuvalent
Aug 8, 2023
Initiates: Market Perform
Price Target: $42
Current: $107.87
Upside: -61.06%